Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous MSCs for GVHD
NCT02359929Phase 1Completed
- Sponsor
- Emory University
- Start
- Jan 2015
- Primary completion
- Jun 2020
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of Provacel in graft-versus-host disease (GVHD) (3 arms), sponsored by Emory University. Primary endpoint: Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs) at 6 months. Started Jan 2015; status: completed.
02
Drugs
Provacel
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02359929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02359929.